ArticlePlastic and reconstructive surgery. Global open2025
Ethosome (ETHOSOMEPTT) Photothermal Therapy with Nd:YAG Laser (Pastelle Pro): A Novel Nanotechnology Approach for Treatment-resistant Melasma.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gold nanoparticles in skin drug delivery: a bibliometric analysis of research trends from 2015 to 2025.Frontiers in medical technology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma poses considerable challenges in dermatologic management, particularly due to variable treatment responses and frequent recurrence following conventional interventions. We describe ethosome photothermal therapy (ETHOSOMEPTT, N-Finders Co., Ltd, Korea), an innovative 5-layer nanosystem that integrates transdermal delivery technology with targeted laser energy. The platform incorporates ethosomes, phospholipid vesicles containing ethanol, with plasmonic gold and platinum nanoparticles to provide dual therapeutic mechanisms: enhanced drug penetration and controlled hyperthermia. Upon activation by specific laser wavelengths, this system generates localized heat while facilitating the delivery of active ingredients to deeper tissue layers relative to conventional topical treatments. A clinical example demonstrates its utility: a 42-year-old woman with persistent malar melasma spanning 6 years, who had undergone treatment with hydroquinone, oral tranexamic acid, and neodymium-doped yttrium aluminum garnet laser with insufficient improvement, demonstrated a 68% reduction in Modified Melasma Area and Severity Index after 12 treatment sessions. Treatment was well tolerated, with transient erythema as the primary side effect. The mechanism underlying ethosome photothermal therapy encompasses ethanol-mediated enhancement of stratum corneum permeability, targeted delivery via plasmonic nanoparticles, and controlled thermal effects on tissue structure. This methodology represents a potential advancement in melasma management, particularly for cases demonstrating limited response to conventional therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.